Key result
Palmitic acid supplementation produced significant decreases in ATP in perfused diabetic hearts compared to controls, suggesting a defect in phosphocreatine metabolism.
Why the study?
Does palmitic acid supplementation alter high-energy-phosphate levels in perfused diabetic hearts compared to control hearts?
Population
Perfused diabetic and control hearts
Comparison
Perfusion with glucose buffer supplemented with… vs Control hearts perfused with the same buffers
Design
Preclinical
Follow-up
1 hour
Authors
Loading...
No clinical implications for diabetes care; hypothesis-generating for phosphocreatine defects in diabetic hearts.
Does palmitic acid supplementation alter high-energy-phosphate levels in perfused diabetic hearts compared to control hearts?
The study suggests a defect in phosphocreatine metabolism in the perfused diabetic heart, potentially related to creatine kinase kinetics, when exposed to increasing palmitate concentrations.
Pieper et al. (1983) studied Diabetes. Palmitic acid supplementation vs. Control hearts / Glucose buffer alone was evaluated on ATP and phosphocreatine levels. Palmitic acid supplementation produced significant decreases in ATP in perfused diabetic hearts compared to controls, suggesting a defect in phosphocreatine metabolism.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: